Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H2W6
UPID:
RM46_HUMAN
Alternative names:
39S ribosomal protein L46, mitochondrial; P2ECSL
Alternative UPACC:
Q9H2W6; B2RD75; Q9HBU8
Background:
The Large ribosomal subunit protein mL46, also known by its alternative names 39S ribosomal protein L46, mitochondrial and P2ECSL, plays a crucial role in the mitochondrial ribosome. As part of the 39S large ribosomal subunit, it is involved in protein synthesis within mitochondria, essential for cellular energy production and metabolic processes.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein mL46 could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis suggests that modulation of its activity could have implications for diseases linked to mitochondrial dysfunction.